Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD
Nisha Joseph, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Molecular Profiling in mHSPC: Informing Treatment Selection
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
Addressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Lyudmila A. Bazhenova, MD
De Novo mHSPC: Recognizing the Patients Who Need More
Case: Implementing ADT Intensification in mHSPC
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
ADT Intensification: The Evidence You Can’t Afford to Miss
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
Assessing and Interpreting pCR in Perioperative NSCLC
Alexander Spira, MD, PhD, FACP
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.